Bone and soft tissue sarcoma mortality in 19 811 patients diagnosed in Japan, 2006-2020
JNCI Cancer Spectrum · 2026
DOI: 10.1093/jncics/pkag001 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2026. Verfasst von Kengo Kawaguchi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Bone Neoplasms, Sarcoma, Soft Tissue Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science KAKENHI, Graduate School of Medical Sciences at Kyushu University.
Abstract (Originalsprache)
Background
Sarcomas are rare malignant tumors with heterogeneous histologies and limited population-based evidence. Although new treatments have been introduced in recent years, their effect on real-world survival outcomes remains unclear. This study aimed to evaluate recent trends in mortality for bone and soft tissue sarcomas in Japan.
Methods
We conducted a cohort study using data from the Bone and Soft Tissue Tumor Registry, a nationwide database maintained by the Japanese Orthopaedic Association. Patients diagnosed with primary sarcomas between 2006 and 2020 were included and grouped by diagnostic period (2006-2010, 2011-2015, 2016-2020). The primary outcome was cumulative mortality risk, estimated using Poisson regression. Subgroup analyses were conducted by age, sex, tumor origin, metastasis status, treatment modality, and histological subtype. Sensitivity analyses included multiple imputation, Kaplan–Meier estimates, and competing risk models.
Results
A total of 19 811 patients were analyzed. No statistically significant change in overall mortality risk was observed across diagnostic periods. Ewing sarcoma showed a consistent decline in mortality, whereas other subtypes did not. Mortality risk was lower in patients who received surgery and higher in those who received radiotherapy or chemotherapy. Results were robust across sensitivity analyses.
Conclusions
Survival outcomes for sarcoma patients in Japan have remained largely unchanged over the past 15 years, except for Ewing sarcoma. Novel therapeutic approaches are needed to achieve meaningful improvements in prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Health Care Administration and Management, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Division of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo, Japan.
- Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
ORCID-Profile: Kengo Kawaguchi, Makoto Endo, Haruhisa Fukuda, Akira Kawai, Toshifumi Fujiwara, Akira Nabeshima, Nobuhiko Yokoyama, Yoshinao Oda, Yasuharu Nakashima
Förderung
- Japan Society for the Promotion of Science KAKENHI
- Graduate School of Medical Sciences at Kyushu University
Zitieren
APA
Kawaguchi, K., Endo, M., Fukuda, H., Kawai, A., Fujiwara, T., Nabeshima, A., Yokoyama, N., Oda, Y., & Nakashima, Y. (2026). Bone and soft tissue sarcoma mortality in 19 811 patients diagnosed in Japan, 2006-2020. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkag001
Vancouver
Kawaguchi K, Endo M, Fukuda H, Kawai A, Fujiwara T, Nabeshima A, et al. Bone and soft tissue sarcoma mortality in 19 811 patients diagnosed in Japan, 2006-2020. JNCI Cancer Spectrum. 2026. doi:10.1093/jncics/pkag001
BibTeX
@article{Kawaguchi2026,
author = {Kawaguchi, Kengo and Endo, Makoto and Fukuda, Haruhisa and Kawai, Akira and Fujiwara, Toshifumi and Nabeshima, Akira and Yokoyama, Nobuhiko and Oda, Yoshinao and Nakashima, Yasuharu},
title = {Bone and soft tissue sarcoma mortality in 19 811 patients diagnosed in Japan, 2006-2020},
journal = {JNCI Cancer Spectrum},
year = {2026},
doi = {10.1093/jncics/pkag001}
}
EUVIMED